Technology

NASA’s SpaceX Crew-8 Launches to International Space Station

Published

2 years ago

March 4, 2024

WASHINGTON, March 4, 2024 /PRNewswire/ — An international crew of four reached orbit following a successful launch to the International Space Station at 10:53 p.m. EST Sunday from Launch Complex 39A at NASA’s Kennedy Space Center in Florida. NASA’s SpaceX Crew-8 mission is the agency’s eighth commercial crew rotation mission with the company to the space station.

A SpaceX Falcon 9 rocket propelled the Dragon spacecraft into orbit carrying NASA astronauts Matthew Dominick, Michael Barratt, and Jeanette Epps, along with Roscosmos cosmonaut Alexander Grebenkin, for a science expedition aboard the orbital laboratory.

“Congratulations to NASA and SpaceX on another successful launch to the International Space Station! On this eighth crew rotation mission, we are once again showing the strength of our commercial partnerships and American ingenuity that will propel us further in the cosmos,” said NASA Administrator Bill Nelson. “Aboard the station, the crew will conduct more than 200 science experiments and technology demonstrations to help fuel this new era of space exploration and benefit humanity here on Earth.”

During Dragon’s flight, SpaceX will monitor a series of automatic spacecraft maneuvers from its mission control center in Hawthorne, California. NASA teams will monitor space station operations throughout the flight from the Mission Control Center at the agency’s Johnson Space Center in Houston. NASA coverage continues with audio only commentary until the start of the rendezvous and docking broadcast.

The Dragon spacecraft, named Endeavour, will dock autonomously to the forward port of the station’s Harmony module about 3 a.m. Tuesday, March 5. NASA will provide live coverage of rendezvous, docking, and hatch opening, beginning at 1 a.m., on NASA+, NASA Television, the NASA app, YouTube, and the agency’s website. NASA also will continue coverage of the crew welcome ceremony once they are aboard the orbital outpost. Learn how to stream NASA TV through a variety of platforms including social media.

Crew-8 will join the space station’s Expedition 70 crew of NASA astronauts Jasmin Moghbeli and Loral O’Hara, ESA (European Space Agency) astronaut Andreas Mogensen, JAXA (Japan Aerospace Exploration Agency) astronaut Satoshi Furukawa, and Roscosmos cosmonauts Konstantin Borisov, Oleg Kononenko, and Nikolai Chubb. For a short time, the number of crew aboard the space station will increase to 11 until Crew-7 members Moghbeli, Mogensen, Furukawa, and Borisov return to Earth a few days later.

Crew-8 will conduct new scientific research to prepare for human exploration beyond low Earth orbit and benefit humanity on Earth. Experiments include a study of brain organoids to understand neurodegenerative disorders, shifts in body fluids during spaceflight, and the effects of UV radiation and microgravity on plant growth. These are just a few of the more than 200 science experiments and technology demonstrations that will take place during their mission.

With this mission, NASA will maximize use of the space station, where astronauts have lived and worked continuously for more than 23 years testing technologies, performing science, and developing the skills needed to operate future commercial destinations in low Earth orbit and explore farther from Earth. Research conducted on the space station provides benefits for people on Earth and paves the way for future long-duration trips to the Moon and beyond through NASA’s Artemis missions.

More about Crew-8
Matthew Dominick is the commander for Crew-8, his first spaceflight since his selection as an astronaut in 2017. During Expedition 70/71 aboard the space station, he will serve as a mission specialist. Follow @dominickmatthew on X.

Michael Barratt is the Crew-8 pilot, making his third visit to the space station. In 2009, Barratt served as a flight engineer for Expeditions 19/20 as the station transitioned its standard crew complement from three to six and performed two spacewalks. He flew aboard the space shuttle Discovery in 2011 on STS-133, which delivered the Permanent Multipurpose Module and fourth Express Logistics Carrier. Barratt has spent a total of 212 days in space. During Expedition 70/71, he will serve as a mission specialist.

Jeanette Epps is a mission specialist for Crew-8, her first spaceflight, working with the commander and pilot to monitor the spacecraft during the dynamic launch and re-entry phases of flight. Epps was selected by NASA as an astronaut in 2009. She will serve as a flight engineer during Expeditions 70/71. Follow @Astro_Jeanette on X.

Roscosmos cosmonaut Alexander Grebenkin is flying on his first mission. He will serve as a flight engineer during Expeditions 70/71.

Learn more about NASA’s SpaceX Crew-8 mission and Commercial Crew Program at:

https://www.nasa.gov/commercialcrew

View original content to download multimedia:https://www.prnewswire.com/news-releases/nasas-spacex-crew-8-launches-to-international-space-station-302078079.html

SOURCE NASA

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

54 minutes ago

April 23, 2026

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

54 minutes ago

April 23, 2026

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

54 minutes ago

April 23, 2026

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system, helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company